Skip to main content
    E

    Elanco Animal Health (ELAN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $26.43
    -0.35 (-1.31%)

    Market Cap: $13.39B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Elanco Animal Health (ELAN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Elanco Animal Health reported revenue of $4.71B for the fiscal year ended Dec 31, 2025, up 6.2% from the year before. That year, net income was -$232.00M with a net margin of -4.9%, operating cash flow was $560.00M and free cash flow was $284.00M. The quarter ended Sep 30, 2026 had revenue of $1.26B and net income of $18.00M.

    Revenue and Margins

    The operating margin was -0.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.91B, a compound annual rate of 5.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.71B+6.2%55.0%-0.1%-4.9%
    Dec 2024$4.44B+0.5%54.9%1.9%7.6%
    Dec 2023$4.42B+0.1%56.3%-20.8%-27.9%
    Dec 2022$4.41B-7.4%56.6%3.8%-1.8%
    Dec 2021$4.76B+45.6%55.2%-7.0%-10.1%
    Dec 2020$3.27B+6.5%49.0%-21.6%-17.5%
    Dec 2019$3.07B+0.1%52.1%6.0%2.2%
    Dec 2018$3.07B+6.2%48.7%4.7%2.8%
    Dec 2017$2.89B-0.8%48.3%-8.1%-10.8%
    Dec 2016$2.91BN/A51.6%-0.9%-1.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.71B$4.44B$4.42B$4.41B$4.76B$3.27B$3.07B$3.07B$2.89B$2.91B
    Cost of revenue$2.12B$2.00B$1.93B$1.91B$2.13B$1.67B$1.47B$1.57B$1.49B$1.41B
    Gross profit$2.59B$2.44B$2.49B$2.50B$2.63B$1.60B$1.60B$1.49B$1.40B$1.50B
    Research and development$368.00M$344.00M$327.00M$321.00M$369.00M$329.00M$270.00M$246.60M$251.70M$265.80M
    Operating income-$4.00M$83.00M-$918.00M$169.00M-$335.00M-$705.00M$185.00M$143.70M-$232.70M-$25.20M
    Net income-$232.00M$338.00M-$1.23B-$78.00M-$483.00M-$574.00M$68.00M$86.50M-$310.70M-$47.90M
    EBITDA$676.00M$1.39B-$224.00M$851.00M$445.00M$80.00M$472.00M$439.70M$85.80M$232.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.26B$1.37B$1.37B$1.14B$1.14B$1.24B$1.19B$1.02B$1.03B$1.18B$1.21B$1.03B
    Gross profit$720.00M$798.00M$785.00M$589.00M$607.00M$713.00M$684.00M$519.00M$538.00M$689.00M$690.00M$519.00M
    Operating income$83.00M$115.00M$144.00M-$202.00M$2.00M$84.00M$112.00M-$14.00M-$23.00M$33.00M$87.00M-$78.00M
    Net income$18.00M$54.00M$57.00M-$276.00M-$34.00M$11.00M$67.00M-$8.00M$364.00M-$50.00M$32.00M-$141.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $4.02B exceeded cash and equivalents by $3.47B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$13.36B$12.61B$14.36B$15.49B$16.48B$17.69B$8.99B$8.96B$8.94B$8.10B
    Current assets$3.46B$3.21B$3.41B$3.28B$3.27B$3.42B$2.37B$2.50B$2.12B$1.95B
    Cash and equivalents$545.00M$468.00M$352.00M$345.00M$638.00M$495.00M$334.00M$474.80M$323.40M$258.80M
    Total liabilities$6.81B$6.52B$8.14B$8.20B$8.97B$9.22B$3.44B$3.76B$1.16B$1.07B
    Short-term debt$74.00M$44.00M$38.00M$388.00M$294.00M$555.00M$24.50M$29.00M$0N/A
    Long-term debt$3.94B$4.28B$5.74B$5.45B$6.03B$5.57B$2.33B$2.44B$0N/A
    Shareholder equity$6.55B$6.10B$6.22B$7.29B$7.51B$8.48B$5.55B$5.20B$7.78B$7.03B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.34B$13.56B$13.22B$13.36B$13.55B$13.74B$12.94B$12.61B$13.28B$13.76B$14.02B$14.36B
    Total liabilities$6.71B$6.97B$6.72B$6.81B$6.80B$6.97B$6.59B$6.52B$6.76B$7.82B$7.96B$8.14B
    Cash and equivalents$465.00M$530.00M$428.00M$545.00M$505.00M$539.00M$487.00M$468.00M$490.00M$416.00M$345.00M$352.00M
    Shareholder equity$6.63B$6.59B$6.50B$6.55B$6.75B$6.78B$6.35B$6.10B$6.52B$5.94B$6.06B$6.22B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 50.7% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$560.00M$541.00M$271.00M$452.00M$483.00M-$41.00M$224.00M$487.30M$173.80M$155.90M
    Capital expenditures$276.00M$147.00M$140.00M$171.00M$159.00M$135.00M$140.00M$134.50M$98.60M$110.30M
    Free cash flow$284.00M$394.00M$131.00M$281.00M$324.00M-$176.00M$84.00M$352.80M$75.20M$45.60M
    Investing cash flow-$279.00M$1.16B-$169.00M-$179.00M-$530.00M-$4.78B-$235.00M-$127.00M-$964.60M-$182.10M
    Financing cash flow-$275.00M-$1.49B-$83.00M-$549.00M$210.00M$4.95B-$305.00M-$35.20M$847.50M-$149.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$216.00M$277.00M$13.00M$108.00M$219.00M$237.00M-$4.00M$177.00M$162.00M$200.00M$2.00M$157.00M
    Capital expenditures$60.00M$33.00M$51.00M$62.00M$92.00M$57.00M$65.00M$47.00M$42.00M$34.00M$24.00M$41.00M
    Free cash flow$156.00M$244.00M-$38.00M$46.00M$127.00M$180.00M-$69.00M$130.00M$120.00M$166.00M-$22.00M$116.00M
    Last 12 quarters

    Frequently Asked Questions About ELAN

    What is Elanco Animal Health's annual revenue?

    Elanco Animal Health reported revenue of $4.71B for the fiscal year ended Dec 31, 2025.

    How fast is Elanco Animal Health's revenue growing?

    Revenue was up 6.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.

    Is Elanco Animal Health profitable?

    No. Elanco Animal Health reported net income of -$232.00M for the fiscal year ended Dec 31, 2025, with a net margin of -4.9%.

    How much free cash flow does ELAN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $560.00M minus capital expenditures of $276.00M produced free cash flow of $284.00M.

    How much debt does Elanco Animal Health have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $3.94B, short-term debt of $74.00M and cash and equivalents of $545.00M.